Qiu F.,Shanghai University |
Qiu F.,Chinese Navy General Hospital |
Li T.,Chinese People's Liberation Army |
Zhang K.,PLA Fourth Military Medical University |
And 3 more authors.
International Immunopharmacology | Year: 2016
Systemic lupus erythematosus is an autoimmune disease with comprehensive immune cell disorders. Recent studies suggested that pro-inflammatory cytokine IL-17 plays important role in lupus, leaving the cellular sources and their pathogenic and physiologic characters largely unknown. In the current study, by using lupus-prone MRL/lpr mice, we demonstrated that Th17 response prevails in lupus disease regarding significantly accumulated serum IL-17, increased IL-17-producing splenocytes, and elevated phospho-STAT3 in CD4+ T cells. Intracellular staining revealed that unusual CD4+ B220+ T cells are major IL-17-producing cells, whereas conventional CD4+ B220- T cells are major IFN-γ-producing cells. Subsequent studies showed that CD4+ B220+ cells contains both αβ and γδ T cells in the spleen and thymus of MRL/lpr mice. Further study showed that around 60% of γδ T cells in MRL/lpr mice co-express both B220 and CD4 on their surface, and are the major RORγt+ cells in MRL/lpr mice. Finally, CD4+ B220+ T cells alone do not proliferate, but could enhance the proliferation and IFN-γ-production of conventional CD4+ B220- T cells. Our findings suggest the pathogenic role of unusual CD4+ B220+ T cells in lupus disease in MRL/lpr mice according to their IL-17-producing ability and stimulatory function for conventional CD4+ B220- T cells. © 2016 Elsevier B.V.
Wang W.-F.,Chinese PLA General Hospital |
Li X.,Chinese PLA General Hospital |
Guo M.-Z.,Chinese PLA General Hospital |
Chen J.-D.,University of Texas Medical Branch |
And 5 more authors.
World Journal of Gastroenterology | Year: 2013
AIM: To investigate mitochondrial ATP 6 and 8 polymorphisms in the colon and ileum of patients with irritable bowel syndrome with diarrhea (IBS-D). METHODS: Twenty-eight patients fulfilling the Rome III criteria for IBS-D and 28 healthy subjects were investigated. All study participants underwent screening colonoscopy and mucosal biopsies were obtained from the colon and/or terminal ileum. Genomic DNA was extracted from specimens based on standard protocols. Mitochondrial ATP (MT-ATP) 6 and 8 genes in specimens were polymerase chain reaction amplified and sequenced. Sequencing data were analyzed via Variant Reporter™ Software and compared with the reference sequence from Genbank (accession No. NC_012920) to indicate possible polymorphisms. The protocol was registered at www.clinicaltrials.gov as NCT01028898. RESULTS: Twenty-five polymorphic sites of MT-ATP 6 and 8 genes were detected and 12 of them were missense mutations. A median of two polymorphic sites in MT-ATP genes was found in colon specimens of controls while a median of three polymorphic sites was noted in patients with IBS-D (Mann-Whitney test, P = 0.012). The variants of the colon and ileum specimens from the same subjects were identical in all but one case. Symptom duration in IBS was not found to be a significant factor associated with the mtDNA polymorphism (Spearman correlation, P = 0.592). The mitochondrial DNA change at 8860 was present in all cases of both groups. The frequency of the 8701 polymorphism was found to be the second most frequent; however, no statistical difference was noted between the groups (χ2 test, P = 0.584). CONCLUSION: Patients with IBS-D have a higher incidence of MT-ATP 6 and 8 polymorphisms than healthy subjects, implying that the mtDNA polymorphism may play a role in IBS-D. © 2013 Baishideng. All rights reserved.
Li T.-T.,Chinese People's Liberation Army |
Qiu F.,Chinese Navy General Hospital |
Qian Z.R.,Dana-Farber Cancer Institute |
Wan J.,Chinese People's Liberation Army |
And 2 more authors.
World Journal of Gastroenterology | Year: 2014
Gastric neuroendocrine tumors (GNETs) are rare lesions characterized by hypergastrinemia that arise from enterochromaffin-like cells of the stomach. GNETs consist of a heterogeneous group of neoplasms comprising tumor types of varying pathogenesis, histomorphologic characteristics, and biological behavior. A classification system has been proposed that distinguishes four types of GNETs; the clinicopathological features of the tumor, its prognosis, and the patient's survival strictly depend on this classification. Thus, correct management of patients with GNETs can only be proposed when the tumor has been classified by an accurate pathological and clinical evaluation of the patient. Recently developed cancer therapies such as inhibition of angiogenesis or molecular targeting of growth factor receptors have been used to treat GNETs, but the only definitive therapy is the complete resection of the tumor. Here we review the literature on GNETs, and summarize the classification, clinicopathological features (especially prognosis), clinical presentations and current practice of management of GNETs. We also present the latest findings on new gene markers for GNETs, and discuss the effective drugs developed for the diagnosis, prognosis and treatment of GNETs. © 2014 Baishideng Publishing Group Co., Limited. All rights reserved.
PubMed | Chinese Navy General Hospital, Xi'an Jiaotong University, PLA Fourth Military Medical University and Chinese People's Liberation Army
Type: | Journal: Mediators of inflammation | Year: 2016
Systemic lupus erythematosus (SLE) is associated with accelerated atherosclerosis and increased cardiovascular risk. Angiogenic T cells (Tang), a specific T cell subset, have been identified and involved in the repair of damaged endothelium. This study aimed to analyze the Tang cell subsets in relation to disease specific features from SLE patients.Tang cell subsets were assessed in peripheral blood samples from 41 SLE patients and 22 healthy controls (HC) by flow cytometry on the basis of CD31 and CXCR4 expression on CD3+, CD4+, and CD8+ T cells.The percentage of circulating CD8+CD31+CXCR4+ T cells (CD8+ Tang), but not CD3+CD31+CXCR4+ T cells (Tang) and CD4+CD31+CXCR4+ T cells (CD4+ Tang), in SLE was higher than HC. The percentages of Tang cell subsets in anti-dsDNA-positive SLE patients were significantly increased as compared to their negative counterparts and HC. Additionally, the levels of circulating Tang cell subsets were negatively correlated with age at sampling and at diagnosis, but not disease duration or disease activity.Anti-dsDNA-positivity may identify a group of SLE patients with increased Tang cell subsets and circulating CD8+ Tang cells may be viewed as a potentially useful biomarker of endothelial damage and cardiovascular risk in SLE.
Song W.-A.,Chinese PLA General Hospital |
Song W.-A.,Chinese Navy General Hospital |
Zhou N.-K.,Chinese PLA General Hospital |
Wang W.,Chinese Navy General Hospital |
And 7 more authors.
Journal of Thoracic Oncology | Year: 2010
INTRODUCTION:: The survival effectiveness of neoadjuvant chemotherapy in non-small cell lung cancer (NSCLC) is still unclear based on the study of most up-to-date literatures. This article contributes to this problem by conducting an updated meta-analysis. METHODS:: Based on Burdett et als (J Thorac Oncol 2006;1:611-621) systematic review, this meta-analysis was conducted. Articles were searched electrically. The possible survival benefit of neoadjuvant chemotherapy was assessed by hazard ratio (HR) in terms of overall survival. A subgroup meta-analysis with only stage III NSCLC was also conducted. The software of Review Manager was used for data management. RESULTS:: Thirteen randomized control trials, 6 of which were new ones, were included into this meta-analysis. The overall survival of NSCLC patients in neoadjuvant chemotherapy arm were improved significantly, comparing with those in surgery-alone arm (combined HR = 0.84; 95% confidence interval, 0.77-0.92; p = 0.0001). When only patients with stage III NSCLC were considered, the result was similar (combined HR = 0.84; 95% confidence interval, 0.75-0.95; p = 0.005). CONCLUSION:: Neoadjuvant chemotherapy, as an addition of surgery, would significantly improve the overall survival of operable NSCLC patients, including patients with stage III NSCLC. Copyright © 2010 by the International Association for the Study of Lung.
Li T.-T.,Chinese PLA General Hospital |
Qiu F.,Chinese Navy General Hospital |
Wang Z.-Q.,Chinese PLA General Hospital |
Sun L.,Chinese PLA General Hospital |
Wan J.,Chinese PLA General Hospital
World Journal of Gastroenterology | Year: 2013
Helicobacter pylori (H. pylori) is a pathogen and the most frequent cause of gastric ulcers. There is also a close correlation between the prevalence of H. pylori infection and the incidence of gastric cancer. We present the case of a 38-year-old woman referred by her primary care physician for screening positron emission tomography-computed tomography (PET-CT), which showed a nodular strong accumulation point with standardized uptake value 5.6 in the gastric fundus. Gastroscopy was then performed, and a single arched ulcer, 12 mm in size, was found in the gastric fundus. Histopathological examination of the lesion revealed chronic mucosal inflammation with acute inflammation and H. pylori infection. There was an obvious mitotic phase with widespread lymphoma. Formal anti-H. pylori treatment was carried out. One month later, a gastroscopy showed a single arched ulcer, measuring 10 mm in size in the gastric fundus. Histopathological examination revealed chronic mucosal inflammation with acute inflammation and a very small amount of H. pylori infection. The mitotic phase was 4/10 high power field, with some heterotypes and an obvious nucleolus. Follow-up gastroscopy 2 mo later showed the gastric ulcer in stage S2. The mucosal swelling had markedly improved. The patient remained asymptomatic, and a follow-up PET-CT was performed 6 mo later. The nodular strong accumulation point had disappeared. Followup gastroscopy showed no evidence of malignant cancer. H. pylori -associated severe inflammation can lead to neoplastic changes in histiocytes. This underscores the importance of eradicating H. pylori, especially in those with mucosal lesions, and ensuring proper follow- up to prevent or even reverse early gastric cancer. © 2013 Baishideng. All rights reserved.
Zhou S.,Chinese Navy General Hospital |
Chen J.,Chinese PLA General Hospital |
Xu R.-Y.,Chinese Navy General Hospital |
Wu H.-Y.,Chinese PLA General Hospital
Patient Preference and Adherence | Year: 2014
Introduction: Rapid reperfusion therapies (RT), particularly percutaneous coronary intervention (PCI), improve short- and long-term outcomes in patients with ST segment elevation myocardial infarction (STEMI). However, a substantial proportion of patients with STEMI, especially older patients, refuse or do not undergo PCI. Our study aims to identify factors associated with the use of PCI in elderly Chinese patients with their first STEMI. Method: Elderly (aged 65 years of age or over) patients with STEMI were enrolled between March 2010 and August 2013 at two hospitals in Beijing. Patients with previous myocardial infarction and those with contraindications to reperfusion were excluded. A standardized questionnaire including onset time and severity of symptoms, history of angina pectoris, comorbid illnesses, functional status, family income, health insurance, education, patients' trust in treating physicians, and whether patient was acquainted with a cardiologist was used to collect data from patients or their family. Results: Five hundred and sixty-eight patients were enrolled. PCI was accepted by 432 (76%) and refused by 136 (24%). Multivariate analysis showed that older age (> 75 years; odds ratio [OR], 0.57; 95% confidence interval [CI], 0.23-0.78), self-rated mild symptoms (OR, 0.12; 95% CI, 0.06-0.21), lower degree of trust in treating physician (<6 in a 10 point scale; [OR, 0.14; 95% CI, 0.09-0.28]), and not being acquainted with a cardiologist (OR, 0.28; 95% CI, 0.07-0.42) were associated with refusal of PCI. Conclusion: PCI was refused by almost one quarter of eligible elderly Chinese patients with a first STEMI. Age, symptom severity, and trust in physician were independent factors associated with the use of PCI in these patients. © 2013 Zhou et al.
Wang L.,Chinese Navy General Hospital |
Wang L.,Ohio State University |
Wang L.,Chinese PLA General Hospital |
Liu J.-Q.,Ohio State University |
And 4 more authors.
OncoImmunology | Year: 2015
Interleukin-10 (IL-10) is a potent anti-inflammatory cytokine that regulates immune responses. IL-10 has also been shown to enhance antitumor CD8+ T-cell responses in tumor models although the underlying mechanisms are not fully understood. In this study, we used a series of genetic mouse models and the mouse plasmacytoma J558 model to investigate this issue. J558 tumors grew significantly faster in IL-10−/− mice than in wild type (WT) mice, but similarly in IL-10−/−Rag2−/− and Rag2−/− mice. Tumors from IL-10−/− mice contained fewer IFN-γ-producing CD8+ and CD4+ T cells than tumors from WT mice. Strikingly, depletion of total CD4+ T cells, but not CD25+ cells, resulted in tumor eradication in IL-10−/− mice. Adoptive transfer studies revealed that CD4+ T cells from IL-10−/− mice exhibited more potent suppression of cytotoxic T lymphocyte (CTL)-mediated tumor rejection than their WT counterparts, and IL-10–deficient tumor-infiltrating CD4+ T cells expressed higher levels of PD-L1 and CTLA-4 inhibitory molecules. Although IL-10–deficient CD8+ T cells are not defective in activation and initial rejection of tumors, adoptive transfer studies using IL-10–deficient P1CTL transgenic T cells that recognize the tumor rejection antigen P1A reveal that IL-10 is required for long-term persistence of CTLs and control of tumor growth. Thus, we have found that IL-10 enhances antitumor CTL responses by inhibiting highly suppressive CD4+ T cells and promoting CTL persistence. These data have important implications for the design of immunotherapy for human. © 2015 Taylor & Francis Group, LLC.
Wang Q.,Chinese PLA General Hospital |
Wang Q.,Chinese Navy General Hospital |
Zeng Y.,Chinese PLA General Hospital |
Wang Y.,Chinese PLA General Hospital |
And 4 more authors.
International Journal of Cardiovascular Imaging | Year: 2011
The purpose of this study was to evaluate the differences in carotid arterial morphology and plaque composition between patients with acute coronary syndrome (ACS) and patients with stable coronary artery disease (SCAD). Twenty-eight patients (12 ACS patients and 16 SCAD patients) underwent carotid high-resolution MRI examination using a 3.0-Tesla (3.0T) MRI scanner. The indicators of carotid arterial morphology included the maximum total vessel area (Max-TVA), mean TVA, minimum lumen area (Min-LA), mean LA, maximum wall area (Max-WA), mean WA, maximum wall thickness (Max-WT), mean WT, maximum normalized wall index (Max-NWI), mean NWI, and maximum stenosis (Max-stenosis). The indicators of plaque composition included the prevalence and mean area percentage (%) of lipid-rich necrotic core (LRNC), calcification (Ca), intraplaque hemorrhage (IPH), and fibrous cap rupture (FCR). None of the indicators of carotid arterial morphology had significant differences (all P>0.05) between the ACS and SCAD patients. The prevalence and plaque composition area percentage of LRNC, Ca, and IPH did not exhibit significant differences between the two groups. However, carotid plaques in the ACS patients presented a higher prevalence of FCR than SCAD patients (P>0.05). This study revealed a similar carotid arterial morphology between ACS and SCAD patients. However, FCR is more common in carotid plaques with ACS than in those with SCAD. Ruptured carotid plaques may be a forewarning factor for those patients who are at high risk of ACS. © 2011 Springer Science+Business Media, B.V.
Wu H.-Y.,Chinese PLA General Hospital |
Yang L.-L.,Chinese PLA General Hospital |
Zhou S.,Chinese Navy General Hospital
BMC Health Services Research | Year: 2010
Background: During the past 2 decades, there has been a rapid proliferation of "health examination center (HEC)" across China. The effects of their services on public's health have not been systemically investigated. This study aimed to assess the impact of periodic health examination (PHE) at HEC on surgical treatment for uterine fibroids in Beijing residents. Methods. We identified 224 patients with a primary diagnosis of uterine fibroids who had surgical treatment at four Level-1 general hospitals in Beijing, from June 1, 2009 to October 20, 2009. Controls were women who did not have surgery for uterine fibroids, matched (1:1 ratio) for age (within 2 years). A standard questionnaire was used to inquire about whether participants had PHE at HEC during the previous 2 years. Results. PHE at HEC within 2 years were associated with surgical treatment for uterine fibroids. Odds ratios was 4.05 (95% CI, 2.61-6.29 P < 0.001), after adjustment for marital status, whether have children, annual family income, health insurance, education level and self-rated uterine fibroids-related symptom severity. Conclusions. Our study showed PHE currently provided at HEC in China were associated with significantly increased use of surgical treatment for uterine fibroids in women. Further studies are needed to assess the effects of PHE on clinical as well as on broad societal outcomes in Chinese in contemporary medical settings. © 2010 Wu et al; licensee BioMed Central Ltd.